SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kamuran Türker, Murat Albayrak, Berna Öksüzoğlu, Elçin Balc, Mustafa C. Oğan, Gülşen İskender, Fevzi Altuntaş, Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma, European Journal of Gastroenterology & Hepatology, 2015, 27, 1, 39

    CrossRef

  2. 2
    Hong Li, Hong-min Zhang, Li-fen Chen, Ya-qin Chen, Ling Chen, Hong Ren, Huai-dong Hu, Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis, Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 1, 80

    CrossRef

  3. 3
    Ya-Wen Yang, Chih-Yuan Lee, Rey-Heng Hu, Po-Huang Lee, Meng-Kun Tsai, Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients, Clinical and Experimental Nephrology, 2014, 18, 1, 144

    CrossRef

  4. 4
    Myung Jin Oh, Heon Ju Lee, A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience, Clinical and Molecular Hepatology, 2013, 19, 1, 51

    CrossRef

  5. 5
    Xiang-Yuan Wu, Xing Li, Zhan-Hong Chen, Jing-Yun Wen, Qu Lin, Yan-Fang Xing, Min Dong, Li Wei, Tian-Tian Wang, Jie Chen, Ze-Xiao Lin, Xiang-bo Wan, Dan-Yun Ruan, Xiao-Kun Ma, An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study, Tumor Biology, 2013, 34, 2, 909

    CrossRef

  6. 6
    Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management, Hepatology International, 2013, 7, 2, 316

    CrossRef

  7. 7
    Gang Huang, Eric C. H. Lai, Wan Yee Lau, Wei-ping Zhou, Feng Shen, Ze-ya Pan, Si-yuan Fu, Meng-chao Wu, Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels, Annals of Surgery, 2013, 257, 3, 490

    CrossRef

  8. 8
    Amanda Abramson, Alan Menter, Robert Perrillo, Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management, Journal of the American Academy of Dermatology, 2012, 67, 6, 1349

    CrossRef

  9. 9
    Ramazan Idilman, Mutlu Arat, Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation, Expert Review of Anti-infective Therapy, 2011, 9, 8, 641

    CrossRef

  10. 10
    Chan Ran You, Jeong Won Jang, Jae Ki Choi, Si Hyun Bae, Seung Kew Yoon, Chul Seung Kay, Jong Young Choi, Hepatic Failure Caused by Reactivation of YMDD Mutants Occurring during Preemptive Lamivudine Therapy, Gut and Liver, 2010, 4, 2, 262

    CrossRef

  11. You have free access to this content11
    John S Lubel, Peter W Angus, Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management, Journal of Gastroenterology and Hepatology, 2010, 25, 5
  12. 12
    Yong Yuan, Uchenna Iloeje, Hong Li, Joel Hay, Guang B. Yao, Economic Implications of Entecavir Treatment in Suppressing Viral Replication in Chronic Hepatitis B (CHB) Patients in China from a Perspective of the Chinese Social Security Program, Value in Health, 2008, 11,
  13. 13
    George K. K. Lau, Hepatitis B reactivation after chemotherapy: two decades of clinical research, Hepatology International, 2008, 2, 2, 152

    CrossRef

  14. 14
    Timucin Cil, Abdullah Altintas, Semir Pasa, Kadim Bayan, Tuncer Ozekinci, Abdurrahman Isikdogan, Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy, Leukemia & Lymphoma, 2008, 49, 5, 939

    CrossRef

  15. 15
    L. H. Katz, A. Fraser, A. Gafter-Gvili, L. Leibovici, R. Tur-Kaspa, Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis, Journal of Viral Hepatitis, 2008, 15, 2
  16. 16
    Lenna A. Martyak, Ehsan Taqavi, Sammy Saab, Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis, Liver International, 2008, 28, 1
  17. 17
    Ali Amouri, Lassaad Chtourou, Leila Mnif, Nabi Tahri, Prise en charge de la réactivation virale B au cours d’un traitement chimiothérapique ou immunosuppresseur, La Presse Médicale, 2008, 37, 11, 1591

    CrossRef

  18. 18
    Holbrook E. Kohrt, Daniel L. Ouyang, Emmet B. Keeffe, Antiviral Prophylaxis for Chemotherapy-Induced Reactivation of Chronic Hepatitis B Virus Infection, Clinics in Liver Disease, 2007, 11, 4, 965

    CrossRef

  19. 19
    J. S. Lubel, A. G. Testro, P. W. Angus, Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management, Internal Medicine Journal, 2007, 37, 10
  20. 20
    Jay H. Hoofnagle, Edward Doo, T. Jake Liang, Russell Fleischer, Anna S.F. Lok, Management of hepatitis B: Summary of a clinical research workshop, Hepatology, 2007, 45, 4
  21. 21
    Sercan Aksoy, Hakan Harputluoglu, Saadettin Kilickap, Didem Sener Dede, Omer Dizdar, Kadri Altundag, Ibrahim Barista, Rituximab-related viral infections in lymphoma patients, Leukemia & Lymphoma, 2007, 48, 7, 1307

    CrossRef

  22. 22
    Gadi Lalazar, Deborah Rund, Daniel Shouval, Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies, British Journal of Haematology, 2007, 136, 5
  23. 23
    Jeong Won Jang, Jong Young Choi, Si Hyun Bae, Seung Kew Yoon, U Im Chang, Chang Wook Kim, Se Hyun Cho, Jun Yeol Han, Young Sok Lee, A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization, Hepatology, 2006, 43, 2
  24. 24
    Winnie Yeo, Philip J. Johnson, Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy, Hepatology, 2006, 43, 2
  25. 25
    Annarosa Floreani, Sara Boninsegna, Salvatore Lobello, Diego Caroli, Stefano Fagiuoli, Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal, Gastroentérologie Clinique et Biologique, 2006, 30, 2, 307

    CrossRef

  26. 26
    Bertrand Coiffier, Hepatitis B Virus Reactivation in Patients Receiving Chemotherapy for Cancer Treatment: Role of Lamivudine Prophylaxis, Cancer Investigation, 2006, 24, 5, 548

    CrossRef

  27. 27
    Yu-Hong Li, Yi-Fu He, Wen-Qi Jiang, Fen-Hua Wang, Xu-Bin Lin, Li Zhang, Zhong-Jun Xia, Xiao-Fei Sun, Hui-Qiang Huang, Tong-Yu Lin, You-Jian He, Zhong-Zhen Guan, Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma, Cancer, 2006, 106, 6
  28. 28
    H. E. KOHRT, D. L. OUYANG, E. B. KEEFFE, Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection, Alimentary Pharmacology & Therapeutics, 2006, 24, 7
  29. 29
    Marc Bourlière, Portage inactif du virus de l’hépatite B, Gastroentérologie Clinique et Biologique, 2005, 29, 4, 369

    CrossRef

  30. 30
    Themistoklis Vassiliadis, Vassilia Garipidou, Konstantinos Tziomalos, Vassilios Perifanis, Olga Giouleme, Sofia Vakalopoulou, Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—A prospective case series, American Journal of Hematology, 2005, 80, 3
  31. 31
    R. Idilman, M. Arat, E. Soydan, M. Törüner, İ. Soykan, H. Akbulut, Ö. Arslan, M. Özcan, A. R. Türkyilmaz, M. Bozdayı, S. Karayalçın, D. H. Van Thiel, A. Özden, M. Beksaç, H. Akan, Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies, Journal of Viral Hepatitis, 2004, 11, 2
  32. 32
    Jeong Won Jang, Jong Young Choi, Si Hyun Bae, Chang Wook Kim, Seung Kew Yoon, Se Hyun Cho, Jin Mo Yang, Byung Min Ahn, Chang Don Lee, Young Sok Lee, Kyu Won Chung, Hee Sik Sun, Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma, Journal of Hepatology, 2004, 41, 3, 427

    CrossRef

  33. 33
    M.B.Y. Tang, K.V.S. Liew, P.P.L. Ng, S.H. Tan, S.K. Ng, Cutaneous polyarteritis nodosa associated with precore mutant hepatitis B infection, British Journal of Dermatology, 2003, 149, 4
  34. 34
    George K.K Lau, Harry H.Y Yiu, Daniel Y.T Fong, Hoi-Ching Cheng, Wing-Yan Au, Lydia S.F Lai, Micheal Cheung, Hai-Ying Zhang, Albert Lie, Roger Ngan, Raymond Liang, Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology, 2003, 125, 6, 1742

    CrossRef

  35. 35
    Geoffrey H. Haydon, David J. Mutimer, Hepatitis B and C virus infections in the immune compromised, Current Opinion in Infectious Diseases, 2003, 16, 5, 473

    CrossRef

  36. 36
    Lior H Katz, Abigail Fraser, Leonard Leibovici, Rani Tur-Kaspa, Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy, The Cochrane Library,
  37. 37
    Lior H Katz, Abigail Fraser, Leonard Leibovici, Rani Tur-Kaspa, Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy, The Cochrane Library,